Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy
| العنوان: | Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy |
|---|---|
| المؤلفون: | R L Heideman, J T Stuntz, F B Ruymann, W A Bleyer, E J Kosnik, A F Mulne, J D Morris, J R Geyer, Thomas W. Pendergrass, J M Milstein |
| المصدر: | Journal of Clinical Oncology. 5:1221-1231 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 1987. |
| سنة النشر: | 1987 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Vincristine, Cyclophosphamide, Dacarbazine, medicine.medical_treatment, Astrocytoma, Neutropenia, Procarbazine, Methylprednisolone, Lomustine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Hydroxyurea, Child, Cisplatin, Chemotherapy, Brain Neoplasms, business.industry, Cytarabine, medicine.disease, Combined Modality Therapy, Surgery, Regimen, Drug Evaluation, Neoplasm Recurrence, Local, Glioblastoma, business, Medulloblastoma, medicine.drug |
| الوصف: | The development of a new multidrug chemotherapy regimen for primary brain tumors was based upon the cellular heterogeneity within individual tumors, the Goldie-Coldman and Price-Goldie-Hill hypotheses, and known agonistic effects of certain drug combinations and sequences. Eight drugs (vincristine [VCR], hydroxyurea, procarbazine, CCNU, cisplatin, cytosine arabinoside [Ara-C] high-dose methylprednisolone, and either cyclophosphamide or dacarbazine) were administered within 12 hours in an attempt to minimize myelosuppression. Courses were repeated at 2- to 4-week intervals. The regimen was devised to include lipid and water soluble drugs, polar and nonpolar agents, phase-specific and cell-cycle independent agents, and antineoplastics with different mechanisms of action. More than 330 courses of the regimen were administered to 107 children with brain tumors whose tumor had recurred or had been incompletely resected at diagnosis. Tumor response according to protocol-specified criteria and independent review was evaluable in 78% of the patients. After just two cycles of chemotherapy and within a 4- to 6-week interval, 50% had an objective tumor response including 15.5% who had a complete response (CR). Nephrotoxicity and high-frequency hearing losses were noted after three to five courses of therapy in approximately half of the patients. Transfusions with red cells or platelets and use of antibiotics for fever and neutropenia were required in 10% to 25% of patients. The regimen appears satisfactory for preradiation chemotherapy in newly diagnosed patients with residual tumor after surgery, but it must be compared with standard therapeutic approaches in prospective controlled trials before its relative value can be established. |
| تدمد: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.1987.5.8.1221 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a97e31a72ce7cd08e58898e3c76fe941 https://doi.org/10.1200/jco.1987.5.8.1221 |
| رقم الانضمام: | edsair.doi.dedup.....a97e31a72ce7cd08e58898e3c76fe941 |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....a97e31a72ce7cd08e58898e3c76fe941 705 3 unknown 705.149597167969 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a97e31a72ce7cd08e58898e3c76fe941&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a97e31a72ce7cd08e58898e3c76fe941# [Name] => EDS - OpenAIRE [Category] => fullText [Text] => View record in OpenAIRE [MouseOverText] => View record in OpenAIRE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22R+L+Heideman%22">R L Heideman</searchLink><br /><searchLink fieldCode="AR" term="%22J+T+Stuntz%22">J T Stuntz</searchLink><br /><searchLink fieldCode="AR" term="%22F+B+Ruymann%22">F B Ruymann</searchLink><br /><searchLink fieldCode="AR" term="%22W+A+Bleyer%22">W A Bleyer</searchLink><br /><searchLink fieldCode="AR" term="%22E+J+Kosnik%22">E J Kosnik</searchLink><br /><searchLink fieldCode="AR" term="%22A+F+Mulne%22">A F Mulne</searchLink><br /><searchLink fieldCode="AR" term="%22J+D+Morris%22">J D Morris</searchLink><br /><searchLink fieldCode="AR" term="%22J+R+Geyer%22">J R Geyer</searchLink><br /><searchLink fieldCode="AR" term="%22Thomas+W%2E+Pendergrass%22">Thomas W. Pendergrass</searchLink><br /><searchLink fieldCode="AR" term="%22J+M+Milstein%22">J M Milstein</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <i>Journal of Clinical Oncology</i>. 5:1221-1231 ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => American Society of Clinical Oncology (ASCO), 1987. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 1987 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Oncology%22">Oncology</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+Research%22">Cancer Research</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22Vincristine%22">Vincristine</searchLink><br /><searchLink fieldCode="DE" term="%22Cyclophosphamide%22">Cyclophosphamide</searchLink><br /><searchLink fieldCode="DE" term="%22Dacarbazine%22">Dacarbazine</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Ftreatment%22">medicine.medical_treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Astrocytoma%22">Astrocytoma</searchLink><br /><searchLink fieldCode="DE" term="%22Neutropenia%22">Neutropenia</searchLink><br /><searchLink fieldCode="DE" term="%22Procarbazine%22">Procarbazine</searchLink><br /><searchLink fieldCode="DE" term="%22Methylprednisolone%22">Methylprednisolone</searchLink><br /><searchLink fieldCode="DE" term="%22Lomustine%22">Lomustine</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Antineoplastic+Combined+Chemotherapy+Protocols%22">Antineoplastic Combined Chemotherapy Protocols</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Hydroxyurea%22">Hydroxyurea</searchLink><br /><searchLink fieldCode="DE" term="%22Child%22">Child</searchLink><br /><searchLink fieldCode="DE" term="%22Cisplatin%22">Cisplatin</searchLink><br /><searchLink fieldCode="DE" term="%22Chemotherapy%22">Chemotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Brain+Neoplasms%22">Brain Neoplasms</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Cytarabine%22">Cytarabine</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22Combined+Modality+Therapy%22">Combined Modality Therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Surgery%22">Surgery</searchLink><br /><searchLink fieldCode="DE" term="%22Regimen%22">Regimen</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+Evaluation%22">Drug Evaluation</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasm+Recurrence%2C+Local%22">Neoplasm Recurrence, Local</searchLink><br /><searchLink fieldCode="DE" term="%22Glioblastoma%22">Glioblastoma</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22Medulloblastoma%22">Medulloblastoma</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edrug%22">medicine.drug</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => The development of a new multidrug chemotherapy regimen for primary brain tumors was based upon the cellular heterogeneity within individual tumors, the Goldie-Coldman and Price-Goldie-Hill hypotheses, and known agonistic effects of certain drug combinations and sequences. Eight drugs (vincristine [VCR], hydroxyurea, procarbazine, CCNU, cisplatin, cytosine arabinoside [Ara-C] high-dose methylprednisolone, and either cyclophosphamide or dacarbazine) were administered within 12 hours in an attempt to minimize myelosuppression. Courses were repeated at 2- to 4-week intervals. The regimen was devised to include lipid and water soluble drugs, polar and nonpolar agents, phase-specific and cell-cycle independent agents, and antineoplastics with different mechanisms of action. More than 330 courses of the regimen were administered to 107 children with brain tumors whose tumor had recurred or had been incompletely resected at diagnosis. Tumor response according to protocol-specified criteria and independent review was evaluable in 78% of the patients. After just two cycles of chemotherapy and within a 4- to 6-week interval, 50% had an objective tumor response including 15.5% who had a complete response (CR). Nephrotoxicity and high-frequency hearing losses were noted after three to five courses of therapy in approximately half of the patients. Transfusions with red cells or platelets and use of antibiotics for fever and neutropenia were required in 10% to 25% of patients. The regimen appears satisfactory for preradiation chemotherapy in newly diagnosed patients with residual tumor after surgery, but it must be compared with standard therapeutic approaches in prospective controlled trials before its relative value can be established. ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1527-7755<br />0732-183X ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1200/jco.1987.5.8.1221 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a97e31a72ce7cd08e58898e3c76fe941" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a97e31a72ce7cd08e58898e3c76fe941</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.1200/jco.1987.5.8.1221" linkWindow="_blank">https://doi.org/10.1200/jco.1987.5.8.1221</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....a97e31a72ce7cd08e58898e3c76fe941 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1200/jco.1987.5.8.1221
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 11
[StartPage] => 1221
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Oncology
[Type] => general
)
[1] => Array
(
[SubjectFull] => Cancer Research
[Type] => general
)
[2] => Array
(
[SubjectFull] => medicine.medical_specialty
[Type] => general
)
[3] => Array
(
[SubjectFull] => Vincristine
[Type] => general
)
[4] => Array
(
[SubjectFull] => Cyclophosphamide
[Type] => general
)
[5] => Array
(
[SubjectFull] => Dacarbazine
[Type] => general
)
[6] => Array
(
[SubjectFull] => medicine.medical_treatment
[Type] => general
)
[7] => Array
(
[SubjectFull] => Astrocytoma
[Type] => general
)
[8] => Array
(
[SubjectFull] => Neutropenia
[Type] => general
)
[9] => Array
(
[SubjectFull] => Procarbazine
[Type] => general
)
[10] => Array
(
[SubjectFull] => Methylprednisolone
[Type] => general
)
[11] => Array
(
[SubjectFull] => Lomustine
[Type] => general
)
[12] => Array
(
[SubjectFull] => Internal medicine
[Type] => general
)
[13] => Array
(
[SubjectFull] => Antineoplastic Combined Chemotherapy Protocols
[Type] => general
)
[14] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[15] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[16] => Array
(
[SubjectFull] => Hydroxyurea
[Type] => general
)
[17] => Array
(
[SubjectFull] => Child
[Type] => general
)
[18] => Array
(
[SubjectFull] => Cisplatin
[Type] => general
)
[19] => Array
(
[SubjectFull] => Chemotherapy
[Type] => general
)
[20] => Array
(
[SubjectFull] => Brain Neoplasms
[Type] => general
)
[21] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[22] => Array
(
[SubjectFull] => Cytarabine
[Type] => general
)
[23] => Array
(
[SubjectFull] => medicine.disease
[Type] => general
)
[24] => Array
(
[SubjectFull] => Combined Modality Therapy
[Type] => general
)
[25] => Array
(
[SubjectFull] => Surgery
[Type] => general
)
[26] => Array
(
[SubjectFull] => Regimen
[Type] => general
)
[27] => Array
(
[SubjectFull] => Drug Evaluation
[Type] => general
)
[28] => Array
(
[SubjectFull] => Neoplasm Recurrence, Local
[Type] => general
)
[29] => Array
(
[SubjectFull] => Glioblastoma
[Type] => general
)
[30] => Array
(
[SubjectFull] => business
[Type] => general
)
[31] => Array
(
[SubjectFull] => Medulloblastoma
[Type] => general
)
[32] => Array
(
[SubjectFull] => medicine.drug
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => R L Heideman
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => J T Stuntz
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => F B Ruymann
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => W A Bleyer
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => E J Kosnik
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => A F Mulne
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => J D Morris
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => J R Geyer
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Thomas W. Pendergrass
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => J M Milstein
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 08
[Type] => published
[Y] => 1987
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 15277755
)
[1] => Array
(
[Type] => issn-print
[Value] => 0732183X
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsair
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 5
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Journal of Clinical Oncology
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |